Axsome Therapeutics
AXSM
36 hedge funds and large institutions have $49.4M invested in Axsome Therapeutics in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 4 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 8
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
13% more capital invested
Capital invested by funds: $43.7M → $49.4M (+$5.71M)
6% more funds holding
Funds holding: 34 → 36 (+2)
Top Buyers
| 1 |
Stifel Financial
St. Louis,
Missouri
|
+$3.14M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$630K |
| 3 |
BWP
Baldwin Wealth Partners
Marion,
Massachusetts
|
+$115K |
| 4 |
JMFC
J.M. Forbes & Co
Boston,
Massachusetts
|
+$114K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$99.7K |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$286K |
| 2 |
Goldman Sachs
New York
|
-$135K |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$104K |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$69.3K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$14K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SO
26
STRS Ohio
Columbus,
Ohio
| $28K | -$757 | -100 | -3% |
|
27
Wells Fargo
San Francisco,
California
| $18K | +$10K | +1,325 | +133% |
|
28
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $14K | +$689 | +91 | +5% |
|
29
Citigroup
New York
| $7K | -$1.58K | -209 | -19% |
|
30
BNP Paribas Financial Markets
Paris,
France
| $5.96K | +$2.39K | +316 | +72% |
|
31
Bank of America
Charlotte,
North Carolina
| $4K | -$6.68K | -882 | -64% |
|
32
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $4K | – | – | – |
|
33
BlackRock
New York
| $3K | – | – | – |
|
|
LTFS
34
Ladenburg Thalmann Financial Services
Miami,
Florida
| $3K | +$2.96K | +391 | New |
|
35
Barclays
London,
United Kingdom
| $1K | +$1.05K | +139 | New |
|
|
TCIM
36
TIAA CREF Investment Management
New York
| $258 | – | – | – |
|
|
37
Goldman Sachs
New York
| – | -$135K | -17,854 | Closed |
|
|
38
Acadian Asset Management
Boston,
Massachusetts
| – | -$14K | -1,909 | Closed |
|
39
UBS Group
Zurich,
Switzerland
| – | -$7K | -937 | Closed |
|
|
TRCT
40
Tower Research Capital (TRC)
New York
| – | -$4K | -481 | Closed |
|
AXSM Hedge Fund Activity: Q3 2016 in Review
36 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q3 2016, worth a combined $49.4M — up 13% from $43.7M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new AXSM positions and 4 closed out — a net gain of 2 holders — while 13 added to existing stakes and 8 trimmed.
The largest buyer was Stifel Financial, opening a new position worth an estimated $3.14M. The largest seller was Morgan Stanley, cutting an estimated $286K.
- 36 institutional investors held Axsome Therapeutics (AXSM) as of Q3 2016, up from 34 in Q2 2016.
- Funds reported $49.4M of Axsome Therapeutics stock for Q3 2016, up 13% quarter-over-quarter.
- 6 funds opened new Axsome Therapeutics positions in Q3 2016 and 4 closed out, a net change of +2 holders.
- The largest Axsome Therapeutics buyer in Q3 2016 was Stifel Financial, an estimated $3.14M added.
- The largest Axsome Therapeutics seller in Q3 2016 was Morgan Stanley, an estimated $286K sold.
Based on aggregated 13F filings for Q3 2016.